s0122188
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- HEDGEHOG_SIGNALING+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- APICAL_JUNCTION+0.200
- GLYCOLYSIS+0.200
- MITOTIC_SPINDLE+0.200
- MYOGENESIS+0.200
- TGF_BETA_SIGNALING+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.300
- PEROXISOME-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- BILE_ACID_METABOLISM-0.200
- E2F_TARGETS-0.200
- HEME_METABOLISM-0.200
- MYC_TARGETS_V1-0.200
- SPERMATOGENESIS-0.200
- ADIPOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CQ-6224-01A-11R-1915-07 | — | — | 0.755 |
| 2 | TCGA-XF-AAMT-01A-11R-A42T-07 | — | — | 0.741 |
| 3 | TCGA-E9-A229-01A-31R-A157-07 | — | A | 0.730 |
| 4 | MNG530 | — | — | 0.712 |
| 5 | TCGA-D8-A73W-01A-22R-A352-07 | — | B | 0.705 |
| 6 | ERR2278864 | — | — | 0.705 |
| 7 | SRR8613792 | — | D | 0.705 |
| 8 | TCGA-AR-A24V-01A-21R-A169-07 | — | A | 0.704 |
| 9 | TCGA-CV-7090-01A-11R-2016-07 | — | — | 0.703 |
| 10 | TCGA-FD-A3SP-01A-31R-A22U-07 | — | — | 0.699 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |